Recent Quotes (30 days)

You have no recent quotes
chg | %

Finance

Results 1 - 20 of about 20 for Novartis AG�
Company Exchange Symbol Last price Quote change Market cap
Valeant Pharmaceuticals Intl Inc NYSE VRX 235.87 +0.97 (0.41%) 80.68B
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, ...
Novartis AG (ADR) NYSE NVS 98.29 -0.33 (-0.33%) 261.05B
Novartis AG is a Switzerland-based company that provides healthcare solutions. The Company operates as a multinational group of companies that specialize in ...
Novartis AG VTX NOVN 94.20 -0.15 (-0.16%) 246.26B
Novartis AG is a Switzerland-based company that provides healthcare solutions. The Company operates as a multinational group of companies that specialize in ...
Valeant Pharmaceuticals Intl Inc TSE VRX 312.05 +1.60 (0.52%) 105.72B
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, ...
NOVARTIS AG BASL OTCMKTS NVSEF 98.35 -0.65 (-0.66%) 265.02B
Celgene Corporation NASDAQ CELG 124.04 +1.00 (0.81%) 98.06B
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, ...
VALEANT PHARMACEUT. INTL FRA BVF 210.10 +2.67 (1.29%)
NOVARTIS AG CEDEAR EACH REP 0.5 ADR BCBA NVS 676.80 0.00 (0.00%)
MorphoSys AG ETR MOR 62.97 -0.57 (-0.90%) 1.62B
... development for diabetic nephropathy and fibrotic diseases, well as five programs in the discovery phase and two pre-development programs with Novartis.
Valeant Pharma SWX VRX 237.30 0.00 (0.00%)
MorphoSys AG FRA MOR 63.21 -0.70 (-1.10%) 1.62B
... development for diabetic nephropathy and fibrotic diseases, well as five programs in the discovery phase and two pre-development programs with Novartis.
Morphosys Ag (ADR) OTCMKTS MPSYY 36.67 0.00 (0.00%) 1.94B
... development for diabetic nephropathy and fibrotic diseases, well as five programs in the discovery phase and two pre-development programs with Novartis.
MORPHOSYS AG OTCMKTS MPSYF 71.01 0.00 (0.00%) 1.88B
MORPHOSYS AG O.N. NEUE ETR MORN 17.48
MORPHOSYS AG O.N. NEUE FRA MORN 17.00
MORPHOSYS AG O.N. NEUE ETR MORA 0.0000
MORPHOSYS AG O.N. NEUE FRA MORA 37.00
CELGENE CORP. DL-,01 FRA CG3 108.76 -0.39 (-0.36%)
Celgene Corp SWX CELG 106.80 0.00 (0.00%)
CELGENE CORP. DL-,01 ETR CG3 109.70 +1.30 (1.20%)